For the fourth time this year, drug manufacturer Lilly has announced refunds for overcharges on 340B-purchased drugs during 2019.
The U.S. Health Resources and Services Administration (HRSA) posted the notice, dated May 27, on the Office of Pharmacy Affairs website last week. Lilly said the 340B ceiling price adjustments for Q4 2019 are due to changes in Medicaid average manufacturer and best price “to account for lagged transactional data.”
For the fourth time this year, drug manufacturer Lilly has announced refunds for overcharges on 340B-purchased drugs during 2019.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.